Clinical Trial

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Study acronym: TONIC-2
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 22, 2022 (before its estimated December 15, 2022 completion). Its status may not reflect the trial's current state.
Summary
This is a single center non-blinded randomized multi-cohort non-comparative phase II trial with a Simon's two-stage design.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-11-07; most recent amendment 2022-03-21.
Status change: Not Yet Recruiting → Recruiting 2020-02-26
Trial Details
NCT Number NCT04159818
Lead Sponsor The Netherlands Cancer Institute
Collaborators: Bristol-Myers Squibb
Conditions Metastatic Breast Cancer
Enrollment 52 participants
Start Date 2020-02-21
Primary Completion 2022-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2022-03-22